Novo Nordisk A/S (NYSE:NVO) Trading Down 1.2% – What’s Next?

Novo Nordisk A/S (NYSE:NVO)’s stock price fell 1.2% on Tuesday . The stock traded as low as $77.52 and last traded at $78.03. 2,310,780 shares traded hands during trading, a decline of 57% from the average session volume of 5,340,098 shares. The stock had previously closed at $78.95.

Analyst Ratings Changes

NVO has been the subject of several research analyst reports. StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. Kepler Capital Markets raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Thursday. Finally, UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. Three research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $145.25.

Novo Nordisk A/S Stock Up 1.3 %

The company has a market capitalization of $339.98 billion, a price-to-earnings ratio of 23.03, a PEG ratio of 0.90 and a beta of 0.42. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74. The business has a 50-day simple moving average of $84.39 and a two-hundred day simple moving average of $103.83.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. As a group, equities analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The company also recently declared a semi-annual dividend, which will be paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st will be paid a dividend of $0.7874 per share. This represents a dividend yield of 1.2%. This is a positive change from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date of this dividend is Monday, March 31st. Novo Nordisk A/S’s payout ratio is 47.72%.

Institutional Investors Weigh In On Novo Nordisk A/S

A number of hedge funds have recently added to or reduced their stakes in the company. Lighthouse Financial LLC acquired a new position in Novo Nordisk A/S during the 4th quarter worth approximately $1,811,000. Aegis Wealth Management LLC acquired a new stake in shares of Novo Nordisk A/S in the 4th quarter valued at approximately $479,000. BridgePort Financial Solutions LLC purchased a new stake in shares of Novo Nordisk A/S in the fourth quarter valued at approximately $540,000. Park Square Financial Group LLC acquired a new position in Novo Nordisk A/S during the fourth quarter worth $29,000. Finally, Employees Retirement System of Texas raised its position in Novo Nordisk A/S by 9.9% in the fourth quarter. Employees Retirement System of Texas now owns 72,964 shares of the company’s stock worth $6,276,000 after acquiring an additional 6,560 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.